+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

Remission of severe tardive dyskinesia in a schizophrenic patient treated with the atypical antipsychotic substance quetiapine

International Clinical Psychopharmacology 15(1): 57-60

In a single inpatient case study, a schizophrenic patient with tardive dyskinesia after prolonged treatment with typical neuroleptics was treated with the new atypical neuroleptic quetiapine, a dibenzothiazepin-derivative. Within 2 weeks of treatment with quetiapine, symptoms of tardive dyskinesia improved; 10 weeks after starting treatment tardive dyskinesia stopped completely. Over the same period, dopamine D2 receptor occupancy decreased substantially, as measured by IBZM-SPECT after 14 and 77 days of treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 011280681

Download citation: RISBibTeXText

PMID: 10836289

DOI: 10.1097/00004850-200015010-00010

Related references

Rapid remission of severe tardive dyskinesia and tardive dystonia with quetiapine. International Journal of Geriatric Psychiatry 20(3): 287-288, 2005

Tardive dyskinesia in a patient treated with quetiapine. World Journal of Biological Psychiatry 10(1): 54-57, 2009

Tardive dyskinesia in children treated with atypical antipsychotic medications. Movement Disorders 22(12): 1777-1782, 2007

Tardive dyskinesia and atypical antipsychotic drugs. Schizophrenia Research 35(SUPPL ): S61-S66, March 1, 1999

Do atypical antipsychotic agents cause tardive dyskinesia?. Journal of Psychosocial Nursing and Mental Health Services 42(10): 14-19, 2004

Tardive Dyskinesia with Atypical Antipsychotic Drugs. Current Drug Therapy 2(3): 168-176, 2007

Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity. Journal of Psychopharmacology 18(1): 124-127, 2004

Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 49(4): 167-173, 2004

Aripiprazole-induced tardive dyskinesia treated with quetiapine: a case report. Acta Neuropsychiatrica 23(4): 188-190, 2011

Tardive dyskinesia occurring in a young woman after withdrawal of an atypical antipsychotic drug. Neurosciences 20(4): 376-379, 2016

Olanzapine induced tardive dyskinesia treated successfully with quetiapine: a case report. Progress in Neuro-Psychopharmacology & Biological Psychiatry 35(1): 276-277, 2011

Tardive dyskinesia caused by the atypical antipsychotic risperidone and cured by the use of another drug of the same class, olanzapine. European Psychiatry 16(4): 259-260, 2001

Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting. Journal of Affective Disorders 150(3): 868-871, 2014

Thalamotomy for severe antipsychotic induced tardive dyskinesia and dystonia. Journal of Neurology, Neurosurgery, and Psychiatry 66(2): 250-251, 1999

Adjunctive quetiapine decreases symptoms of tardive dyskinesia in a patient taking risperidone. Clinical Neuropharmacology 26(6): 297-298, 2003